Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Parvaneh Vossough is active.

Publication


Featured researches published by Parvaneh Vossough.


Tumor Biology | 2007

Overexpression of Orphan Receptor Tyrosine Kinase Ror1 as a Putative Tumor-Associated Antigen in Iranian Patients with Acute Lymphoblastic Leukemia

Mahdi Shabani; Hossein Asgarian Omran; Mahmood Jeddi-Tehrani; Parvaneh Vossough; Mohammad Faranoush; Ramazan Ali Sharifian; Gholam R. Toughe; Mahin Kordmahin; Jalal Khoshnoodi; Azam Roohi; Narjes Tavoosi; Håkan Mellstedt; Hodjatallah Rabbani; Fazel Shokri

Receptor tyrosine kinases (RTKs) are a group of enzymes involved in a variety of physiological and pathological processes. The human Ror1 is a member of the RTK family with unknown ligand and biological function. Overexpression of Ror1 has recently been reported in B-cell chronic lymphocytic leukemia. The aim of this study was to explore the expression profile of Ror1 in acute lymphoblastic leukemia (ALL) cells. Therefore, leukemic cells were isolated from the bone marrow and/or peripheral blood (PB) of 57 ALL patients. Immunophenotyping was performed by flow cytometry and mRNA expression was detected by RT-PCR. Overexpression of Ror1 mRNA was detected in 23 of 57 (40%) ALL patients. A similar expression pattern was observed in ALL cell lines, with 4 of 12 (33%) being positive. Stimulation of normal PB mononuclear cells with pokeweed mitogen and phorbol myristate acetate induced substantially higher Ror1 mRNA expression compared to unstimulated cultured cells. There has been neither a significant association between Ror1 expression and the immunophenotypic profile of the leukemic cells, nor with other clinical or hematological features of the patients. In conclusion, our findings propose Ror1 as a new tumor-associated antigen and a potential tool for targeted immunotherapy and monitoring of minimal residual disease in ALL.


Pediatric Hematology and Oncology | 2008

ENDOCRINOPATHIES IN PATIENTS WITH TRANSFUSION-DEPENDENT ß-THALASSEMIA

Azim Mehrvar; A. Azarkeivan; M. Faranoush; N. Mehrvar; J. Saberinedjad; Raheb Ghorbani; Parvaneh Vossough

Thalassemia is common in Iran. Appropriate therapy for this disease includes a regular blood transfusion and chelation therapy. However, in this approach patients will inevitably experience side effects, particularly iron overloads in critical organs, including heart, ductless glands, and liver. This study attempted to determine prevalence of adenoidal abnormality between Iranian thalassemia patients for prediagnosis and to offer necessary medical measures. This is a descriptive nonrandomized study and included all the patients suffering from thalassemia major referring to medical centers linked with the Iranian blood transfusion organization from January 2004 to January 2005. All patients were sampled for CBC, FBS, 2-h BS, HbAlC, liver function, renal function, and endocrine disease. Initially, reports of adenoidal experiments as well as other associated parameters were provided from medical records. A total of 437 patients enrolled in the study: 5.4% suffered from diabetes, 1% had hypothyroid, and 1 person showed hypoparathyroidism. The mean levels of ferritin in diabetic and nondiabetic groups and hypothyroid and nonhypothyroid groups were not significantly different. The mean levels of ferritin among various age groups also were not significantly different. Results of a comparison between present research and similar studies conducted throughout Iran and those performed abroad on adenoidal abnormalities in thalassemia patients show that subject patients of this study statistically suffered from fewer difficulties than diabetes patients in other studies.


Pediatric Blood & Cancer | 2014

Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries: A prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA)

Naima A. Al-Mulla; Prem Chandra; Mohammed Khattab; Faris Madanat; Parvaneh Vossough; Eyad Torfa; Zakiya Al-Lamki; Gamal Zain; Samar Muwakkit; Salah Mahmoud; Abdulrahman Al-Jassmi; Murat Tuncer; Hussein Al-Mukharraq; Sihem Barsaoui; Robert J. Arceci; Scott C. Howard; Andreas E. Kulozik; Yaddanapudi Ravindranath; Gregory H. Reaman; Mohammad Farranoush; Abdullah Al‐Nasser

Little is known about childhood ALL in the Middle East. This study was undertaken by MECCA as initial efforts in collaborative data collection to provide clinical and demographic information on children with ALL in the Middle East.


Pediatric Hematology and Oncology | 2005

AGGRESSIVE INTRA-ABDOMINAL FIBROMATOSIS IN CHILDREN AND RESPONSE TO CHEMOTHERAPY

Mardawig Alebouyeh; Farideh Moussavi; Ahmad Kahlegh-Nejad Tabari; Parvaneh Vossough

Intra-abdominal fibromatosis (IAF) is a rare benign neoplasm arising from the abdominal fibrous tissue, mostly in the mesentery. IAF is characterized by a tendency to infiltrate the surrounding vessels and vital structures and recurrence after usually incomplete surgical removal. Accordingly, IAF is associated with considerable morbidity and mortality. The authors report on a boy who presented with a large IAF at the age of 5 years. Within 6 months after initial presentation, he underwent 4 subsequent abdominal explorations for diagnosis, tumor reduction, and intestinal obstructions. IAF was confirmed by the presence of vimentin and absence of other biological cell markers. Due to accelerated tumor growth and deteriorated general condition, as a last resort, a chemotherapy trial with vincristin and methotrexate was carried out. This regimen proved to be effective in reducing the tumor burden and improving the patients general condition. Outcome of IAF depends on early diagnosis and complete tumor resection, and, if indicated, timely employment of neo/adjuvant chemotherapy. Radiotherapy must be considered in life-threatening conditions as the last resort in a growing child [234].


Cancer Immunology, Immunotherapy | 2009

Low representation of Fc receptor-like 1–5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia

Tohid Kazemi; Hossein Asgarian-Omran; Ali Memarian; Mahdi Shabani; Ramazan Ali Sharifian; Parvaneh Vossough; Bita Ansaripour; Hodjatallah Rabbani; Fazel Shokri

Recent studies have demonstrated expression of Fc receptor-like (FCRL) molecules, a newly identified family with preferential B-cell lineage expression, in some chronic B-cell leukemias with possible implication for classification and/or targeted immunotherapy. In this study, the expression pattern of FCRL1-5 genes was studied in 73 Iranian ALL patients and 35 normal subjects using semi-quantitative RT-PCR method. FCRL protein expression was also investigated by flow cytometry. Our results indicate significant down-regulation of all FCRL genes in ALL compared to normal subjects. Although, FCRL mRNA expression was almost exclusively confined to normal isolated B-cells compared to T-cells, but these genes were similarly expressed in B-ALL, T-ALL and different B-ALL immunophenotypic subtypes. Surface protein expression of FCRL1, 2, 4, and 5 molecules in 10 ALL and 5 normal samples confirmed the PCR results. Expression profile of FCRL molecules in different subtypes of ALL argues against their potential implication as suitable targets for classification and/or immunotherapy of ALL.


Pediatric Hematology and Oncology | 2002

ACUTE LYMPHOBLASTIC LEUKEMIA AND HEPATOBLASTOMA IN A FAMILY

Khadijeh Arjmandi Rafsanjani; Parvaneh Vossough

Acute lymphoblastic leukemia is the most common and hepatoblastoma is a rare malignancy diagnosed in children. Their report on an Iranian boy with acute lymphoblastic leukemia diagnosed at the age of 2 years; 20 months later his 10-month-old sister was referred to their hospital with hepatoblastoma. The occurrence of such two types of cancer is rare in a family.


Leukemia & Lymphoma | 2008

Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia.

Mahdi Shabani; Hossein Asgarian-Omran; Parvaneh Vossough; Ramazan Ali Sharifian; Mohammad Faranoush; Soheila Ghragozlou; Jalal Khoshnoodi; Azam Roohi; Mahmood Jeddi-Tehrani; Håkan Mellstedt; Hodjatallah Rabbani; Fazel Shokri


Leukemia Research | 2006

Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL)

Maryam Beigom Mobasheri; Mohammad Hossein Modarressi; Mahdi Shabani; Hossein Asgarian; Ramezan-Ali Sharifian; Parvaneh Vossough; Fazel Shokri


Iranian Journal of Immunology | 2007

Immunophenotypic Subtyping of Leukemic Cells from Iranian Patients with Acute Lymphoblastic Leukaemia: Association to Disease Outcome

Hossein Asgarian Omran; Mahdi Shabani; Tahereh Shahrestani; Abdolfattah Sarafnejad; Jalal Khoshnoodi; Parvaneh Vossough; Mahmood Jeddi-Tehrani; Fazel Shokri


Leukemia & Lymphoma | 2008

Cross-sectional monitoring of Wilms' tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission

Hossein Asgarian Omran; Mahdi Shabani; Parvaneh Vossough; Ramazan Ali Sharifian; Mina Tabrizi; Jalal Khoshnoodi; Mahmood Jeddi-Tehrani; Hodjatallah Rabbani; Fazel Shokri

Collaboration


Dive into the Parvaneh Vossough's collaboration.

Top Co-Authors

Avatar

Håkan Mellstedt

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar

Prem Chandra

Hamad Medical Corporation

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Faris Madanat

King Hussein Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eyad Torfa

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Gregory H. Reaman

Children's National Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ibrahim Qaddoumi

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Neil O’Brien

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge